JP2012508698A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508698A5
JP2012508698A5 JP2011535880A JP2011535880A JP2012508698A5 JP 2012508698 A5 JP2012508698 A5 JP 2012508698A5 JP 2011535880 A JP2011535880 A JP 2011535880A JP 2011535880 A JP2011535880 A JP 2011535880A JP 2012508698 A5 JP2012508698 A5 JP 2012508698A5
Authority
JP
Japan
Prior art keywords
seq
peptide
composition
amino acid
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011535880A
Other languages
English (en)
Japanese (ja)
Other versions
JP5750373B2 (ja
JP2012508698A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2009/050304 external-priority patent/WO2010054667A1/en
Publication of JP2012508698A publication Critical patent/JP2012508698A/ja
Publication of JP2012508698A5 publication Critical patent/JP2012508698A5/ja
Application granted granted Critical
Publication of JP5750373B2 publication Critical patent/JP5750373B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011535880A 2008-11-17 2009-11-17 慢性炎症性応答の調節および自己免疫疾患の処置のためのil−4由来ペプチド Active JP5750373B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200801601 2008-11-17
DKPA200801601 2008-11-17
PCT/DK2009/050304 WO2010054667A1 (en) 2008-11-17 2009-11-17 Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases

Publications (3)

Publication Number Publication Date
JP2012508698A JP2012508698A (ja) 2012-04-12
JP2012508698A5 true JP2012508698A5 (enExample) 2012-12-13
JP5750373B2 JP5750373B2 (ja) 2015-07-22

Family

ID=41510516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011535880A Active JP5750373B2 (ja) 2008-11-17 2009-11-17 慢性炎症性応答の調節および自己免疫疾患の処置のためのil−4由来ペプチド

Country Status (12)

Country Link
US (1) US8546321B2 (enExample)
EP (1) EP2365983B1 (enExample)
JP (1) JP5750373B2 (enExample)
CN (1) CN102216323B (enExample)
AU (1) AU2009316076B2 (enExample)
BR (1) BRPI0921717A2 (enExample)
CA (1) CA2743394C (enExample)
ES (1) ES2620437T3 (enExample)
IL (1) IL212962A0 (enExample)
NZ (1) NZ592943A (enExample)
RU (1) RU2542375C2 (enExample)
WO (1) WO2010054667A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
CA2980087A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
US12600757B2 (en) 2017-04-07 2026-04-14 Bioniz Therapeutics, Inc. Peptides inhibiting gamma-c-cytokine activity and methods of use
KR102095284B1 (ko) * 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체
EP3530320B1 (en) 2018-02-27 2023-11-15 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Novel il-4-/il-13-derived peptide compounds for the treatment or prevention of neurodegenerative or neuroinflammatory diseases
CN110746507B (zh) * 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
CA3137971A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
CN118401250A (zh) 2022-01-05 2024-07-26 塞罗德斯有限公司 用于治疗肥胖症的il-4衍生肽
AU2023262616B2 (en) * 2022-04-29 2024-07-11 Serodus Aps Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503088A (ja) * 1989-11-21 1993-05-27 ザ ユニバーシティー オブ メルボルン 抗炎症用の組成物及び方法
ATE136906T1 (de) * 1989-12-20 1996-05-15 Schering Corp Antikörperantagonisten gegen humanes interleukin- 4
US6337072B1 (en) * 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
EP1156823B1 (en) * 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US20030056244A1 (en) * 2000-05-02 2003-03-20 Ning Huang Feed additive compositions and methods
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
JP2007537989A (ja) * 2003-10-16 2007-12-27 アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 安定化ペプチド

Similar Documents

Publication Publication Date Title
JP2012508698A5 (enExample)
AU2022311814A1 (en) Lipidated peptide inhibitors of interleukin-23 receptor
CN103501805B (zh) 调节γ-C-细胞因子活性的组合物及方法
CA2809900C (en) Use of interleukin-22 in treating viral hepatitis
JP2020002154A5 (enExample)
RU2011121971A (ru) Пептиды-производные ил-4 для модуляции хронического воспалительного ответа и лечения аутоиммунных заболеваний
CN104066440B (zh) 白介素-22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
WO2007047791A2 (en) Monomeric self-associating fusion polypeptides and therapeutic uses thereof
JP2013513377A5 (enExample)
JP2008507298A5 (enExample)
CN103596584A (zh) 多取代的胰岛素
AU2023255027A1 (en) Modulating gamma-C-cytokine activity
JP2022500078A5 (enExample)
JP2006506942A5 (enExample)
JP2009112314A5 (enExample)
JP2014529399A5 (enExample)
JP2026035575A (ja) 長時間作用型インターロイキン-15融合タンパク質、その調製方法およびその用途
CA3240982A1 (en) Peptide inhibitors of interleukin-23 receptor
JP2011528334A5 (enExample)
JP2022513321A5 (enExample)
JP2009544304A5 (enExample)
CA3180251A1 (en) Cytokine conjugates
JP2006523432A5 (enExample)
JP2014515595A5 (enExample)
JP2015533372A5 (enExample)